Acuvail

Acuvail is a brand name of ketorolac ophthalmic, approved by the FDA in the following formulation(s):

ACUVAIL (ketorolac tromethamine - solution/drops; ophthalmic)

• 
  Manufacturer: ALLERGAN
  
  Approval date: July 22, 2009
  
  Strength(s): 0.45% ^[RLD]

Has a generic version of Acuvail been approved?

No. There is currently no therapeutically equivalent version of Acuvail available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Acuvail. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Ketorolac tromethamine compositions for treating ocular pain
  Patent 7,842,714
  Issued: November 30, 2010
  Inventor(s): Farnes; Eldon Q. & Attar; Mayssa & Schiffman; Rhett M. & Chang; Chin-Ming & Graham; Richard S. & Welty; Devin F.
  Assignee(s): Allergan, Inc.
  The present invention provides an aqueous ophthalmic solution having an effective amount of ketorolac which includes carboxymethyl cellulose in an aqueous solution wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
  
  Patent expiration dates:
  
  
  • August 15, 2029
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 22, 2012 - NEW PRODUCT
  
  

See also...

• Acuvail Consumer Information (Drugs.com)
• Acuvail Drops Consumer Information (Wolters Kluwer)
• Acuvail Consumer Information (Cerner Multum)
• Acuvail Advanced Consumer Information (Micromedex)
• Ketorolac Drops Consumer Information (Wolters Kluwer)
• Ketorolac Tromethamine Drops Consumer Information (Wolters Kluwer)
• Ketorolac ophthalmic Consumer Information (Cerner Multum)
• Ketorolac Ophthalmic Advanced Consumer Information (Micromedex)
• Ketorolac Tromethamine eent AHFS DI Monographs (ASHP)